Neurocrine Biosciences, Inc. (NBIX) Presents At Cantor Global Healthcare Conference 2025 Transcript

Company Highlights - Neurocrine expects $2.5 billion in sales for INGREZZA this year, indicating strong market performance [3] - The launch of CRENESSITY, the first new medicine in over 70 years for congenital adrenal hyperplasia, has started off strongly [3] - Neurocrine has initiated two major Phase III programs: one for osavampator targeting major depressive disorder and another for a muscarinic program related to schizophrenia [4]